OnKure Therapeutics, Inc. (OKUR)

US — Healthcare Sector
Peers: TPST  KZR  FGEN  PDSB  XLO  ATNM  ALGS  MRSN  BRNS  CVM 

Automate Your Wheel Strategy on OKUR

With Tiblio's Option Bot, you can configure your own wheel strategy including OKUR - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.

Start Your Free Trial Now

Key Metrics & Ratings

  • symbol OKUR
  • Rev/Share 0.0
  • Book/Share 0.4909
  • PB 6.4571
  • Debt/Equity 0.0103
  • CurrentRatio 11.4497
  • ROIC -1.2303

 

  • MktCap 42889973.0
  • FreeCF/Share -0.4539
  • PFCF -0.6983
  • PE -6.4492
  • Debt/Assets 0.0094
  • DivYield 0
  • ROE -0.7846

 

  • Rating C+
  • Score 2
  • Recommendation Sell
  • P/E Score 1
  • DCF Score 5
  • P/B Score 2
  • D/E Score 3

Recent Analyst Ratings

Type Ticker Analyst Firm Previous Rating Current Rating Previous Price Target Current Price Target Date
Initiation OKUR Evercore ISI -- Outperform -- -- April 30, 2025
Initiation OKUR Leerink Partners -- Outperform -- $33 Dec. 5, 2024
Initiation OKUR Oppenheimer -- Outperform -- $35 Oct. 10, 2024

News

OnKure Therapeutics Reports First Quarter 2025 Financial Results and Business Highlights
OKUR
Published: May 06, 2025 by: GlobeNewsWire
Sentiment: Neutral

-- Continued progress in the PIKture-01 trial; on track to report additional data in the second half of 2025, including mature single agent and initial combination data

Read More
image for news OnKure Therapeutics Reports First Quarter 2025 Financial Results and Business Highlights

About OnKure Therapeutics, Inc. (OKUR)

  • IPO Date
  • Website https://onkuretherapeutics.com
  • Industry Biotechnology
  • CEO Nicholas A. Saccomano
  • Employees 46
OnKure, Inc. engages in the discovery and development of oncology-precision medicines for the treatment of cancer. The company focuses on developing selective inhibitors of histone deacetylases. Its portfolio includes OKI-179, an inhibitor for the treatment of both hematological and solid tumors. The company was incorporated in 2011 and is based in Boulder, Colorado.